Effect of AAT on GVHD severity and mortality. (A) AAT treatment scheme. (B) Survival. Survival of AAT-treated mice versus albumin-treated controls (n = 15 each group, P = .04). (C) Severity of GVHD. GVHD was scored based on percentage of weight loss, skin integrity, posture, mobility, and fur texture. Clinical signs were graded on a scale of 0 to 2, where 0 was absent, 1 was moderate, 2 was severe, and the individual scores were added. Shown are GVHD clinical scores for 30 days after transplantation (mean ± SEM per time point; D) Change in body weight of transplanted mice over time after transplantation (mean ± SEM; n = 15). (E) Donor chimerism. Proportion of donor cells among PBMCs in AAT-treated (n = 6) versus albumin-treated (n = 5) mice at day 45 (P = .25).